.png)
Intragastric balloons (IGBs) have emerged as a non-surgical option for weight management, offering an alternative to invasive bariatric procedures. With increasing global obesity rates, the demand for minimally invasive weight-loss solutions is rising. The market has seen rapid advancements in balloon technology, new entrants, and growing regulatory approvals.
The U.S. and Europe are the dominant markets, with key players such as Apollo Endosurgery, Allurion Technologies, and Obalon Therapeutics leading innovation. According to recent healthcare data, more than 650 million adults worldwide suffer from obesity, increasing the demand for weight-loss interventions.
This article explores leading companies, market trends, regional insights, and future opportunities in the intragastric balloon sector.
What Are Intragastric Balloons?
Intragastric balloons are soft, expandable medical devices placed in the stomach to reduce food intake and promote weight loss. They are filled with either saline or gas and remain in place for 6 to 12 months before removal. Unlike bariatric surgery, IGBs are reversible, minimally invasive, and require less downtime.
- Primary Users: Obese patients with a BMI of 30-40 kg/m² who struggle with diet and exercise alone.
- Effectiveness: Clinical studies report an average weight loss of 10-15% of total body weight after six months.
- Safety: Common side effects include nausea, vomiting, and abdominal discomfort, but severe complications are rare.
USA’s Growing Intragastric Balloon Market
The U.S. is a major market for intragastric balloons, driven by rising obesity rates, increasing awareness, and technological advancements.
- Obesity Rates: Over 42% of U.S. adults suffer from obesity, according to the CDC.
- Regulatory Approvals: The FDA approved the first IGBs in 2015, allowing non-surgical treatment options.
- Market Growth: The demand for IGBs is increasing as insurance coverage expands.
Key Companies in the U.S. Market
- Apollo Endosurgery (Austin, Texas) – A pioneer in endoscopic weight-loss solutions, manufacturer of Orbera®.
- Obalon Therapeutics (California) – Known for its gas-filled, swallowable IGB system.
- Allurion Technologies (Massachusetts) – Creator of the Elipse Balloon, the first swallowable, self-absorbing IGB.
Regional Market Share and Opportunities
North America
- Market Share: The U.S. and Canada dominate, with an estimated 60-65% market share.
- Opportunities: Increased insurance reimbursement for IGB procedures, expanding bariatric centers.
Europe
- Market Share: Holds 20-25% of the global market, with key players in France, Italy, and Germany.
- Opportunities: Government-backed obesity awareness programs, rising medical tourism.
Asia-Pacific
- Market Share: 10-15%, but growing rapidly due to rising obesity rates in China and India.
- Opportunities: Expanding healthcare access and affordability of endoscopic procedures.
Latin America & Middle East
- Market Share: 5-10%, with Brazil and UAE leading in weight-loss procedures.
- Opportunities: Increasing medical tourism and lower costs for IGB treatments.
Global Growth Insights unveils the top global Intragastric Balloons Companies:
| Company | Headquarters | Notable Product | Latest Market Update |
|---|---|---|---|
| Apollo Endosurgery | USA | Orbera® Balloon | Acquired by Boston Scientific in 2023 |
| Helioscopie Medical Implants | France | Heliosphere BAG | Focused on European market expansion |
| Spatz FGIA | USA | Spatz3 Adjustable Balloon | Only adjustable IGB approved in multiple regions |
| Allurion Technologies | USA | Elipse Balloon | Expanded operations in Asia & Middle East |
| Districlass Medical | France | Gastric Balloons | Increasing market presence in Europe |
| Endalis | France | Endalis Balloon | New developments in next-gen IGB technology |
| Fengh Medical | China | Gas-Filled IGBs | Entering the European market |
| Lexal Srl | Italy | Custom IGBs | Strong Italian market presence |
| Duomed Group | Belgium | Various Weight Loss Solutions | Focus on digital weight loss integration |
| Medicone | Germany | Medical Balloons | Expanding R&D for next-gen IGBs |
| Medsil | Russia | Medsil IGB | Growing presence in Asia |
| Obalon Therapeutics | USA | Swallowable IGB | FDA re-approval in 2023 |
| Phagia Technologies | USA | Novel Intragastric Devices | Early-stage development phase |
| PlenSat | USA | Weight Loss Devices | Developing smart balloon technology |
| ReShape Medical | USA | ReShape Duo | Merging technology with AI-driven weight management |
Conclusion
The intragastric balloon market is rapidly growing, driven by increasing obesity rates, advancements in medical technology, and expanding insurance coverage. The U.S. remains a key player, but Europe and Asia-Pacific are emerging as strong contenders due to medical tourism and improving healthcare access.
Key players such as Apollo Endosurgery, Allurion Technologies, and Obalon Therapeutics continue to drive innovation, making non-surgical weight-loss solutions more accessible to patients worldwide.
The future of IGBs looks promising, with next-generation adjustable, swallowable, and AI-integrated balloons expected to revolutionize the weight-loss industry.